What question did this study set out to answer?

To evaluate whether universal neonatal ocular prophylaxis with erythromycin ointment remains necessary given advances in prenatal screening and rising antimicrobial resistance.

January 24, 2023Expert Review of Anti-infective Therapy

Neonatal ocular prophylaxis in the United States: is it still necessary?

View Full Paper

Ask AI

Bookmark

Authors

SFSusannah Franco MHMargaret R. Hammerschlag

Discussion

Member takes

Overview

Review reveals limited efficacy of routine erythromycin ocular prophylaxis in newborns, suggesting that prenatal maternal screening provides superior protection.

Key Points

To evaluate whether universal neonatal ocular prophylaxis with erythromycin ointment remains necessary given advances in prenatal screening and rising antimicrobial resistance.
Reviewed historical and current epidemiological trends of ophthalmia neonatorum caused by Neisseria gonorrhoeae and Chlamydia trachomatis in the United States.
Evaluated the pharmacokinetics, physiologic constraints, and efficacy data of 0.5% erythromycin ophthalmic ointment alongside maternal screening guidelines.
Erythromycin 0.5% ophthalmic ointment provides no clinical protection against Chlamydia trachomatis and is increasingly compromised by macrolide-resistant Neisseria gonorrhoeae strains.
Routine prenatal screening and maternal treatment established over recent decades have substantially reduced neonatal conjunctivitis incidence, rendering mandatory universal newborn prophylaxis unsupported by modern evidence.

Cite This Study

Franco et al. (2023) studied this question.

synapsesocial.com/papers/6a82b788040bdabcf346fe3d https://doi.org/10.1080/14787210.2023.2172401

View Full Paper

Ask AI

Bookmark

January 24, 2023Expert Review of Anti-infective Therapy

Neonatal ocular prophylaxis in the United States: is it still necessary?

View Full Paper

Ask AI

Bookmark

Authors

SFSusannah Franco MHMargaret R. Hammerschlag

Discussion

Member takes

Overview

Review reveals limited efficacy of routine erythromycin ocular prophylaxis in newborns, suggesting that prenatal maternal screening provides superior protection.

Key Points

To evaluate whether universal neonatal ocular prophylaxis with erythromycin ointment remains necessary given advances in prenatal screening and rising antimicrobial resistance.
Reviewed historical and current epidemiological trends of ophthalmia neonatorum caused by Neisseria gonorrhoeae and Chlamydia trachomatis in the United States.
Evaluated the pharmacokinetics, physiologic constraints, and efficacy data of 0.5% erythromycin ophthalmic ointment alongside maternal screening guidelines.
Erythromycin 0.5% ophthalmic ointment provides no clinical protection against Chlamydia trachomatis and is increasingly compromised by macrolide-resistant Neisseria gonorrhoeae strains.
Routine prenatal screening and maternal treatment established over recent decades have substantially reduced neonatal conjunctivitis incidence, rendering mandatory universal newborn prophylaxis unsupported by modern evidence.

Cite This Study

Franco et al. (2023) studied this question.

synapsesocial.com/papers/6a82b788040bdabcf346fe3d https://doi.org/10.1080/14787210.2023.2172401

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark